DESCOVY FOR PREP
emtricitabine/tenofovir DF (FTC/TDF)
CDC recommended for prevention of HIV for people at high risk through sex, excluding people at risk through receptive vaginal sex
One tablet once daily, without regard to food. Tablet contains 200 mg emtricitabine and 25 mg tenofovir alafenamide.
Take a missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Descovy should not be used if CrCl is less than 30 mL/min or if you are on dialysis. In children weighing less than 77 pounds, taking Descovy with a boosted HIV protease inhibitor medication is not recommended. Descovy was approved for HIV prevention (pre-exposure prophylaxis, or PrEP) in October 2019.
Gilead Sciences, Inc.
(800) GILEAD-5 (445–3235)
• See the individual drugs contained in Descovy: Emtriva (but TAF is not available separately for HIV).
• See package insert for more complete information on potential side effects and interactions.
Overall, Descovy is well tolerated, but some may experience nausea, headache, stomach pain, or weight loss. Skin discoloration on palms and soles may also occur. May affect the bones and kidneys. In clinical trials, fewer bone and kidney issues were observed with the TAF formulation compared to the TDF formulation. Tell your provider about any pain in extremities, persistent or worsening bone pain and fractures, with or without muscular pain or weakness, as well as any concerning changes in urinary habits as these could be signs of kidney problems. If you have HIV and HBV, guidelines recommend treatment for both viruses. Descovy can be used to treat HIV and HBV simultaneously. If you are co-infected with HBV and HIV, you should not stop Descovy without medical supervision because it can cause your HBV to flare and cause you to experience signs and symptoms of acute hepatitis. HBV should be closely monitored by your provider.
Do not take with Epivir-HBV, Hepsera, or Vemlidy (TAF), used for the treatment of hepatitis B. Use caution with drugs that negatively affect the kidneys, including chronic use or high doses of anti-inflammatory drugs for pain like Advil or Motrin (ibuprofen) and Aleve (naproxen). Descovy should not be taken with certain anticonvulsants (including carbamazepine, oxcarbazepine, phenobarbital, and phenytoin), Aptivus/Norvir, rifabutin, rifampin, rifapentine, or St. John’s wort. Can be used with hepatitis C drugs such as Epclusa, Harvoni, Sovaldi, Olysio, Daklinza, Viekira Pak, or Zepatier. Tell your provider or pharmacist about all medications, herbals, and supplements you are taking or thinking of taking, prescribed or not, as there are other drug interactions which are not listed here.
On October 3, 2019, the U.S. Food and Drug Administration approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. Descovy is not indicated in individuals at risk of HIV-1 infection from receptive vaginal sex because the effectiveness in this population has not been evaluated.
PrEP is short for pre-exposure prophylaxis, which means protecting yourself from exposure to the HIV virus. Descovy is an HIV drug that has proven to reduce the risk of getting infected with HIV. It is prescribed to be taken once a day, every day. Adherence is very important for PrEP to work. You have to be tested before using Descovy for PrEP and every three months see your health care provider who will test you for HIV and other sexually transmitted diseases (STDs). Descovy for PrEP does not reduce the risk for contracting STDs; that’s why it is strongly recommended to practice safer sex practices even if you take Descovy for PrEP.